Neonatal diabetes due to potassium channel mutation: Response to sulfonylurea according to the genotype.

Laure Garcin Veronica MericqAnne-Laure Fauret-AmsellemHelene CaveMichel PolakJacques Beltrand

Published in: Pediatric diabetes (2020)

Sulfonylureas are an effective treatment for monogenic diabetes due to KCNJ11 and ABCC8 genes mutations. The success of the treatment is conditioned by differences in pharmacogenetics, younger age, pharmacokinetics, compliance, and maximal dose used.

Keyphrases

type diabetes
cardiovascular disease
heart rate
combination therapy
blood pressure
weight loss
replacement therapy